Enveric Biosciences Inc, a biotechnology company focused on neuropsychiatric treatment development, has secured five new U.S. patents for its EVM301 portfolio. This latest additions bring Enveric’s total to nine issued U.S. patents, enhancing the intellectual property surrounding its library of neuroplasticity-focused compounds aimed at mental health conditions.
